Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer—Reply

Arjona‐Sánchez, Álvaro

doi:10.1001/jamasurg.2023.3486

Cited by 1 publication

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While our consensus discourages oxaliplatin-based IPCT, specifically of short duration, a conditional recommendation for mitomycin-based IPCT was made [70]. The ASCO guidelines do not propose an alternative IPCT regimen [103].…”

Section: National Perspectivesmentioning

confidence: 99%

“…Trials have yielded conflicting evidence. HIPECT4 demonstrated improved locoregional recurrence-free survival with surgical resection and prophylactic mitomycin C HIPEC compared to resection alone, while PROPHYLOCHIP and COLOPEC trials did not demonstrate a benefit with prophylactic oxaliplatin HIPEC [70][71][72]. Emerging evidence from the ICARuS trial sheds light on Early Postoperative Intraperitoneal Chemotherapy (EPIC) as an additional IPCT modality for CRC-PM and appendiceal cancer [73].…”

Section: Block 6: No Progression After Systemic Therapy With Complete...mentioning

confidence: 99%

See 1 more Smart Citation

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases

Turaga

2024

Preprint

View full text Add to dashboard Cite

Background The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC-PM). Methods An update of the 2018 Chicago Consensus Guidelines was conducted using a modified Delphi technique. Two rounds of voting were performed to assess agreement levels on two clinical management pathways regarding synchronous and metachronous CRC-PM. Supporting evidence was evaluated via rapid literature reviews. Results The overall level of evidence was low in existing literature. Of 145 participants in the first round, 136 (96.8%) responded in the second round. Over 90% consensus was achieved in most pathway blocks. For both pathways, early referral to a peritoneal surface malignancy (PSM) center should be made for patients with CRC-PM. For the synchronous pathway, upfront cytoreductive surgery was de-emphasized in favor of systemic therapy. For the metachronous pathway, risk stratification via clinical and pathologic features was revised. For both pathways, surveillance strategies were added, including only a weak recommendation for circulating tumor DNA (ctDNA) testing given limited evidence of its utility in detecting and monitoring PM. Conclusion The consensus-driven clinical pathways provide valuable guidance for the management of CRC-PM. There remains a need for high-quality evidence and prospective multicenter trials in this domain.

show abstract

Section: National Perspectivesmentioning

confidence: 99%

Section: Block 6: No Progression After Systemic Therapy With Complete...mentioning

confidence: 99%

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases

Turaga

2024

Preprint

View full text Add to dashboard Cite

show abstract

Efficacy, Safety, and Analysis Issues in a Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer—Reply

Cited by 1 publication

References 3 publications

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases

Consensus Guideline for the Management of Colorectal Cancer with Peritoneal Metastases

Contact Info

Product

Resources

About